Clinical trial
A Study of SR58611A in the Prevention of Depression Relapse in Patients With…
NCT00345098 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00345098 |
|---|---|
| Title | A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder |
| Official title | A Double-Blind, Multi-Center, Multinational, Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A (350mg q12) Versus Placebo in the Prevention of Depression Relapse up to 1 Year in Patients With Major Depressive Disorder Improved After 12 Weeks of Open Treatment With SR58611A… |
| Acronym | CALYPSO |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major Depression |
| Intervention type | Drug |
| Interventions | SR58611A |
| Enrollment | 704 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jun 27, 2006 |
| Last update posted | Mar 12, 2009 |
| Countries | Argentina, Bulgaria, Croatia, Czechia, Finland, France, Mexico, Poland, Romania, Russia, Serbia, Slovakia and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: